Compare
Orasure Technologies Inc vs Anika Therapeutics, Inc. vs Beta Bionics, Inc. vs NeuroPace Inc
| Latest fiscal year | Orasure Technologies Inc OSUR | Anika Therapeutics, Inc. ANIK | Beta Bionics, Inc. BBNX | NeuroPace Inc NPCE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $115.02M | $112.82M | $100.25M | $99.99M |
| Revenue growth (YoY) | -38.1% | -5.9% | +53.9% | +25.1% |
| Gross margin | 41.9% | 56.6% | 55.4% | 77.2% |
| Operating margin | -62.6% | -9.8% | -71.5% | -16.3% |
| Net margin | -59.8% | -9.6% | -73.0% | -21.5% |
| Net income | -$68.73M | -$10.88M | -$73.20M | -$21.46M |
| EPS (Diluted) | -$0.94 | -$0.76 | -$1.81 | -$0.66 |
| Operating cash flow | -$49.02M | $11.19M | -$50.92M | -$11.01M |
| Free cash flow | -$53.22M | $4.36M | -$56.22M | -$11.34M |
| Cash & equivalents | $199.28M | $57.48M | $31.58M | $21.69M |
| Total assets | $403.17M | $190.27M | $328.74M | $105.56M |
| Total liabilities | $62.34M | n/a | $41.13M | $86.53M |
| Shareholders' equity | $340.83M | $143.47M | $287.61M | $19.03M |
| Return on year-end equity | -20.2% | -7.6% | -25.5% | -112.8% |
| Shares outstanding | 70.39M | 13.89M | 44.36M | 33.57M |
Revenue, most recent five fiscal years
| Fiscal year | Orasure Technologies Inc | Anika Therapeutics, Inc. | Beta Bionics, Inc. | NeuroPace Inc |
|---|---|---|---|---|
| Latest | $115.02M Ended 2025-12-31 | $112.82M Ended 2025-12-31 | $100.25M Ended 2025-12-31 | $99.99M Ended 2025-12-31 |
| 1 year earlier | $185.83M Ended 2024-12-31 | $119.91M Ended 2024-12-31 | $65.12M Ended 2024-12-31 | $79.91M Ended 2024-12-31 |
| 2 years earlier | $405.47M Ended 2023-12-31 | $120.79M Ended 2023-12-31 | $11.99M Ended 2023-12-31 | $65.42M Ended 2023-12-31 |
| 3 years earlier | $387.48M Ended 2022-12-31 | $113.83M Ended 2022-12-31 | n/a | $45.52M Ended 2022-12-31 |
| 4 years earlier | $233.67M Ended 2021-12-31 | $147.79M Ended 2021-12-31 | n/a | $45.18M Ended 2021-12-31 |